Intrexon (NYSE:XON) had its target price increased by JMP Securities from $42.00 to $43.00 in a research report sent to investors on Wednesday morning. They currently have a market outperform rating on the biotechnology company’s stock.

XON has been the topic of a number of other research reports. Zacks Investment Research upgraded Intrexon from a hold rating to a buy rating and set a $16.00 target price on the stock in a research note on Thursday, August 16th. ValuEngine upgraded Intrexon from a sell rating to a hold rating in a research note on Monday, September 24th. Stifel Nicolaus began coverage on Intrexon in a research note on Tuesday, July 17th. They issued a buy rating and a $72.00 target price on the stock. Finally, Bank of America downgraded Intrexon from a neutral rating to an underperform rating and set a $12.00 target price on the stock. in a research note on Monday, July 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $29.67.

Shares of NYSE XON opened at $15.12 on Wednesday. The company has a current ratio of 1.78, a quick ratio of 1.53 and a debt-to-equity ratio of 0.01. Intrexon has a one year low of $10.26 and a one year high of $20.16. The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of -16.43 and a beta of 1.09.

Intrexon (NYSE:XON) last issued its earnings results on Thursday, August 9th. The biotechnology company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.28). Intrexon had a negative net margin of 82.17% and a negative return on equity of 16.67%. The firm had revenue of $45.30 million during the quarter, compared to analysts’ expectations of $51.70 million. During the same quarter last year, the firm earned ($0.16) EPS. On average, equities research analysts anticipate that Intrexon will post -0.79 EPS for the current fiscal year.

In other news, insider Helen Sabzevari sold 8,402 shares of the company’s stock in a transaction dated Wednesday, July 18th. The stock was sold at an average price of $14.54, for a total transaction of $122,165.08. Following the completion of the sale, the insider now owns 25,000 shares in the company, valued at approximately $363,500. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 48.20% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Third Security LLC boosted its stake in shares of Intrexon by 0.3% during the 2nd quarter. Third Security LLC now owns 59,309,806 shares of the biotechnology company’s stock worth $826,779,000 after acquiring an additional 177,101 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Intrexon by 76.8% during the 2nd quarter. BlackRock Inc. now owns 4,647,554 shares of the biotechnology company’s stock worth $64,788,000 after acquiring an additional 2,019,142 shares in the last quarter. Morgan Stanley boosted its stake in shares of Intrexon by 6.7% during the 2nd quarter. Morgan Stanley now owns 3,118,444 shares of the biotechnology company’s stock worth $43,470,000 after acquiring an additional 196,999 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Intrexon by 123.1% during the 2nd quarter. Northern Trust Corp now owns 917,510 shares of the biotechnology company’s stock worth $12,791,000 after acquiring an additional 506,186 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Intrexon by 31.3% during the 2nd quarter. Bank of America Corp DE now owns 738,264 shares of the biotechnology company’s stock worth $10,291,000 after acquiring an additional 176,105 shares in the last quarter. Institutional investors own 84.92% of the company’s stock.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Further Reading: What are the risks of holding treasury bonds?

Analyst Recommendations for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.